Ask about this productRelated genes to: Wnt1 Blocking Peptide
- Gene:
- WNT1 NIH gene
- Name:
- Wnt family member 1
- Previous symbol:
- INT1
- Synonyms:
- -
- Chromosome:
- 12q13.12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-03-18
Related products to: Wnt1 Blocking Peptide
Related articles to: Wnt1 Blocking Peptide
- The fruit fly Drosophila melanogaster is widely used to study conserved developmental and cellular signaling pathways in vivo. Many signaling pathways, including Wnt signaling, depend on tightly regulated secretion, endocytosis, and intracellular trafficking events. However, visualizing the dynamics of membrane-associated proteins within intact epithelial tissues such as wing imaginal discs remains challenging because of the small size and densely packed columnar organization of these cells. Here, we present a protocol combining three-dimensional stimulated emission depletion (3D STED) nanoscopy with Uptake assays and pharmacological perturbations in Drosophila wing imaginal discs. This workflow enables super-resolution imaging of membrane-associated protein dynamics within intact tissue architecture at near-isotropic resolution. Using Wingless-secreting cells as an example, we visualize the localization and trafficking of Wingless (Wg) at the apical membrane. To analyze dynamic trafficking processes, the imaging workflow is combined with an uptake assay that selectively labels proteins undergoing secretion and reinternalization within a defined time window. In combination with chemical inhibitors and visualization using 3D STED nanoscopy, this approach enables functional analysis of membrane trafficking dynamics. Together, this workflow provides a versatile framework for studying membrane organization and protein trafficking at subcellular resolution in whole tissue samples of Drosophila. - Source: PubMed
Publication date: 2026/10/01
Holzem MichaelaPavlović BojanaStrein ClaudiaLampe MarkoBoutros Michael - Microcystins (MCs) are a class of monocyclic heptapeptide natural toxins produced by freshwater cyanobacteria. They can enter the human body via contaminated water or food. Currently, MCs are recognized by the World Health Organization as health risk factors, with microcystin-leucine-arginine (MC-LR) being the most prevalent and toxic. Our previous research demonstrated that chronic MC-LR exposure reduced dopamine (DA) release from dopaminergic neurons in the substantia nigra, causing Parkinson's disease (PD)-like motor dysfunction in mice. Motor dysfunction is closely linked to reduced DA levels. However, the molecular mechanism by which MC-LR reduces DA release remains unknown. Furthermore, whether serum MC-LR levels are a risk factor for PD in general population and correlates with patients' motor dysfunction warrants further investigation. After DA is synthesized within dopaminergic neurons, it is stored in synaptic vesicles through vesicular monoamine transporter 2 (VMAT2). The stability of VMAT2 requires retromer complex and its core component VPS35. We demonstrate that MC-LR directly binds to VPS35, destabilizing the retromer and leading to increased VMAT2 lysosomal degradation. Concurrently, MC-LR inhibits the Wnt1/β-catenin signaling pathway by downregulating Wnt1, further reducing VPS35 transcription and VMAT2 levels. These effects collectively reducing dopamine levels. To further evaluate the clinical relevance between MC-LR and PD, a cross-sectional study in a human population was conducted. The results showed that elevated serum MC-LR levels are associated with an increased PD risk and motor dysfunction. Integrating evidence from in vivo, in vitro, and human population studies, this study establishes a link between MC-LR exposure and PD. - Source: PubMed
Publication date: 2025/12/31
Wu TongYan MinghaoLiu YiWu HuifangMa ChengxiaoLiu XuekunGuo YangZhang HuiyaLiu YifanXu YunZhang YangHan Xiaodong - - Source: PubMed
Publication date: 2026/10/01
- The incidence of gastric cardia adenocarcinoma (GCA) has increased with increasing prevalence of metabolic syndrome (MetS). Peroxisome proliferator-activated receptor-delta (PPAR-δ) emerged as a key target in MetS and carcinogenesis. We aimed to elucidate its role in GCA progression. - Source: PubMed
Publication date: 2026/09/28
Tanabe MizukiUno KanameTamahara ToruAsano NaokiKoshiba SeizoKusano KeisukeOgasawara KoyaKaise YumikoSaito MasahiroKoike TomoyukiShimizu RitsukoMasamune Atsushi - Idiopathic pulmonary fibrosis (IPF) remains a progressive and fatal disease despite major advances in antifibrotic therapy. Pirfenidone and nintedanib slow lung function decline, and the PDE4B inhibitor nerandomilast and treprostinil have recently shown promise as next-generation treatments. However, current therapies neither halt nor reverse disease progression, and tolerability issues often limit adherence. We compared the antifibrotic activity and plasma levels of nintedanib administered by either oral gavage or dietary supplementation in a rat model of pulmonary fibrosis. Male Sprague-Dawley rats received intratracheal bleomycin (1 U/kg) on days 0 and 4. From day 7 to day 28, animals were treated with nintedanib (100 mg/kg/day) by either oral gavage or medicated chow. Lung weight, fibrosis biomarkers (procollagen-I, metalloproteinase-7 or MMP7, WNT1-inducible signaling pathway protein or WISP-1), epithelial injury marker KL-6, target engagement biomarkers (Fibroblast Growth Factor 2 or FGF-2, Vascular Endothelial Growth Factor or VEGF), plasma drug levels, and histological fibrosis scores were evaluated. Both administration regimens significantly reduced procollagen-I, WISP-1 and KL-6, and histological fibrosis scores. Oral gavage produced approximately fourfold-higher peak plasma concentrations of nintedanib 30 min after dosing, whereas dietary administration resulted in lower, more stable plasma levels with reduced variability while resulting in comparable antifibrotic efficacy. In conclusion, nintedanib retained robust antifibrotic activity when administered via dietary supplementation despite lower, but continuous, active plasma concentrations. Collectively, these findings indicate that optimizing drug delivery and absorption kinetics may achieve sustained therapeutic efficacy while reducing unnecessary exposure to supratherapeutic concentrations, thereby potentially improving tolerability. - Source: PubMed
Publication date: 2026/09/13
Pitozzi VanessaCaruso PaolaPontis SilviaRuscitti FrancescaPittelli Maria GloriaAquino GiancarloVolta RobertaPappani AliceBarrea MariarosariaQuaini FedericoLagrasta Costanza Anna MariaNogara Antonella MariaSpagnolo PaoloTrevisani Marcello